Friday, 16 October 2026European Markets

BYGGMA Stock Was 9% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with BYGGMA (BMA.OL) rising 9% to kr21.80 on Friday while Oslo Børs Benchmark Index_GI rose 0.04% to kr1,304.37.

BYGGMA's last close was kr20.00, 37.3% under its 52-week high of kr31.90.

About BYGGMA

Byggma ASA manufactures and supplies building materials in Norway, Sweden, Denmark, Finland, the United Kingdom, the Netherlands, and internationally. It offers pre-painted ceilings and wall panels under the Huntonit brand name; I-beams for use in ceilings, walls, and floors in wood-based buildings under the brand name of Masonite; and particle boards, boards, and structural panels for use in buildings, interior ceilings, and wall panels under the Forestia brand name. The company also provides home lighting products under the Scan Lamps brand name; doors and windows for new buildings, extensions, and rehabilitation under the brand name of Uldal; a range of lamp and lighting products under the Aneta brand name; and develops, manufactures, and distributes MDF panels for walls, ceilings, bathrooms, and kitchens under the brand name of Smartpanel, as well as supplies OSB plywood and building boards under the brand name of Byggform. It exports its products. Byggma ASA is headquartered in Vennesla, Norway. Byggma ASA operates as a subsidiary of Investor As.

Earnings Per Share

As for profitability, BYGGMA has a trailing twelve months EPS of kr2.05.

PE Ratio

BYGGMA has a trailing twelve months price to earnings ratio of 10.63. Meaning, the purchaser of the share is investing kr10.63 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 28.78%.

Moving Average

BYGGMA's worth is below its 50-day moving average of kr24.22 and way under its 200-day moving average of kr26.65.

Earnings Before Interest, Taxes, Depreciation, and Amortization

BYGGMA's EBITDA is 31.03.

More news about BYGGMA (BMA.OL).

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com